European Journal of Molecular & Clinical Medicine

Abstract

Introduction :
Cancer associated with colon is one of the principal risk factors from decease in women and men. Although importancegrowing aspect of human epidermis receptor2 (Her2)as atherapeutic target is rising butits role as a biomarker in form of predicting indicator indicatorwithin colorectal cancer(CRC)is stilla mystery.Present research isundertakenfor evaluating the of Her2/neu description in cancer of colon.
Material & Method :
This research comprises 256patientswith spectrum of histopathological treatment ranging from colitis to colorectal carcinoma at our department between 2015- 2017. Her2/neu Immunohistochemistry was done in the colorectal carcinomaand scores based on Ruschoff et al (2012) Her-2 testing in gastric cancer.
Result :
Out of total number of 256 cases enrolled in our study group, majority belonged to the age group of 40-60 years, with M:F ratio being 1.4:1. Commonest site of lesion occurred in rectum (43.75%) followed by ascending colon and caecum (12.08%). Non neoplastic lesions constituted about two third of all cases, the commonest being inflammatory bowel disease(21.48%). In benign neoplastic lesions of tubular adenoma was thecommonest type, and in malignant commonest type was colorectal adenocarcinoma NOS(64.44%) followed by mucinous adeno carcinoma (22.22%). Because of more prominent membranous staining observed in high grade colorectal cancers, Her2neu expression is found to be an important predictive marker of carcinoma colon, especially the adenocarcinoma,NOS.
Conclusion : Like Breast carcinoma, target oriented therapy can be instituted especially in Her 2/neu positive high grade and metastatic tumors.